Table 1.

Demographic and clinical results for patients included in the analysis.

CharacteristicPlacebo, n = 69Adalimumab, n = 67
Age, yrs48 ± 1250 ± 14
Male, n (%)39 (57)38 (57)
Minimal disease activity criteria, mean ± SD
  TJC (0–78)28 ± 1826 ± 19
  SJC (0–76)16 ± 1217 ± 13
  PASI (0–72)8 ± 77 ± 6
  HAQ (0–3)1.10 ± 0.681.10 ± 0.64
  Pain (0–100 mm)49 ± 2352 ± 21
  PaGA (0–100 mm)48 ± 2348 ± 23
  Enthesitis* (0–4)1.0 ± 1.40.8 ± 1.3
Physician global assessment category, n (%)
  Clear00
  Almost clear1 (1.5)1 (1.5)
  Mild9 (13.2)12 (17.9)
  Mild to moderate19 (27.9)15 (22.4)
  Moderate25 (36.8)17 (25.4)
  Moderate to severe11 (16.2)19 (28.4)
  Severe3 (4.4)3 (4.5)
  • * Plantar fascia and Achilles tendon insertion. HAQ: Health Assessment Questionnaire; PASI: Psoriasis Activity and Severity Index; PaGA: patient global assessment of disease activity; SJC: swollen joint count; TJC: tender joint count.